New 1,500 square meter facility granted operational authorization from AIFA, the Italian Medicines Agency, to enable production scales of up to 3,000 liters.
U.S.-based, state-of-the-art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic.